Cutting-Edge Cardiac Biomarker Assays Enhance Cardiovascular Diseases Care

Heart-related diseases, or cardiovascular diseases (CVDs), are the number one cause of death across the globe. Early detection is crucial for saving lives. Medical guidelines suggest using high-sensitivity troponin I (hs-cTnI) and NT-proBNP as critical markers for identifying possible Acute Coronary Syndrome (ACS) and heart failure. These markers are essential for quick diagnosis, evaluating risk, and guiding treatment. Now, two new cutting-edge hs-cTnI and NT-proBNP assays aim to enhance the diagnosis and management of CVDs.

Mindray (Shenzhen, China) and its subsidiary HyTest, a global leader in antibodies and antigens, have collaborated to create these new assays. HyTest has been recognized for its expertise in cardiac biomarkers and had its troponin complex designated as the international standard by AACC in 2004. Both of the newly developed assays have been validated by Wuhan Asian Heart Hospital in China and Hennepin Healthcare Research Institute in the United States, showing excellent clinical performance.

The hs-cTnI test from Mindray exceeds the minimum requirements for hs-cTn, achieving an impressive 93% detection rate in the range between LoD and the 99th URL. Additionally, it has an imprecision CV under 5% at the 99th URL, proving its high sensitivity, accuracy, and dependability for spotting heart muscle damage. Moreover, a diagnostic study focusing on a 0-2 hour timeframe, carried out at Hennepin Healthcare Research Institute, supports its efficacy in diagnosing and managing heart conditions within this critical period. On the other hand, NT-proBNP is a well-established marker for heart failure management. Mindray's NT-proBNP test shows a high level of accuracy with a CV of ≤5% and successfully minimizes the impact of 55 common heart medications, making it a reliable tool for the detection and management of heart failure.

"Through integrating HyTest's pioneering antibodies and research on cardiac biomarkers with Mindray's advanced reagent technology and platform, we will deliver more reliable solutions that bring improved patient outcomes in the field of cardiovascular diseases and beyond," said Dr. Jianwen He, Chief Scientific Officer of Mindray IVD.

Related Links:
Mindray